What the Lawsuits Allege
The Bard PowerPort, sometimes called a BardPort, is an implantable port catheter placed just under the skin to provide long-term, repeated access to a patient bloodstream, commonly used for chemotherapy or other regular intravenous treatments. The lawsuits, consolidated as MDL 3081 in the District of Arizona before Judge David G. Campbell, allege the device catheter material, which combines polyurethane with barium sulfate, degrades over time in a way that makes it prone to fracture, migration within the body, and related complications including bloodstream infections, thrombosis, and embolism.
Plaintiffs allege the device makers, Bard Access Systems and parent company Becton Dickinson, knew or should have known about these risks but continued marketing the device as safe without adequate warnings to physicians and patients. More than 3,000 cases are pending in the MDL as of mid-2026, with the number having grown substantially over the prior year.
The First Bellwether Trial: A Genuinely Mixed Result
The first bellwether trial in the MDL began April 21, 2026, in Arizona federal court, involving a plaintiff who alleged a bloodstream infection connected to the device required hospitalization, surgical removal, and delays in cancer treatment. This is worth describing accurately rather than as a clean win for either side, because it was not one.
The jury found in Bard favor on the failure-to-warn and failure-to-instruct claims, and rejected a consumer fraud claim, which count as wins for the defense. However, the jury could not reach a unanimous verdict on the central design-defect claim, meaning that core question, whether the PowerPort itself was defectively designed, remains legally unresolved from this trial. Some jurors reportedly indicated afterward that they believed the device could have been made safer, suggesting the hung result was closer to the plaintiffs position than the partial defense verdict alone might suggest.
Where Things Stand Now
Additional bellwether trials are scheduled through 2027, including cases focused specifically on catheter fracture and thrombosis injuries, distinct from the infection-focused first trial. Legal commentary following the first trial noted that infection-based claims may face tougher going with juries than fracture or migration claims, which could shape how remaining bellwether cases and future settlement negotiations unfold.
No global settlement has been reached, and the parties have been directed to participate in settlement discussions later in 2026, though the unresolved design-defect question from the first trial adds real uncertainty to how those talks may proceed. Because the litigation remains genuinely unresolved rather than headed toward a clear outcome, and filing deadlines vary by state, a prompt, honest case evaluation with an attorney is the practical next step for anyone affected.
How to Get Legal Help
If you had a Bard PowerPort or similar implantable port catheter and experienced complications such as infection, catheter fracture, migration, or a blood clot, gather your medical records identifying the specific device and documenting the complication and any related treatment, since this is central to any potential claim. An attorney experienced in this litigation can evaluate your situation given both the early trial result and your state filing deadline.
To follow any further developments, bookmark this page and subscribe to LawsuitWatch alerts.
Free Legal Evaluation
Do You Qualify to File a Claim?
Our network of verified plaintiff attorneys offers free, no-obligation case evaluations. Contingency fee representation means you pay nothing unless you win.
Bard Port Lawsuit: What the First Bellwether Trial Actually Showed: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
What does the Bard PowerPort lawsuit allege?
That the implantable port catheter, made of polyurethane blended with barium sulfate, degrades over time and is prone to fracture, migration, and complications like infection and blood clots, and that the makers, Bard Access Systems and Becton Dickinson, knew about the risk but failed to adequately warn patients and physicians.
What happened in the first trial?
A genuinely mixed result. The jury found for Bard on failure-to-warn and consumer fraud claims but could not reach a verdict on the central design-defect claim, meaning that key question remains unresolved rather than settled in either side favor.
Does the first trial result mean the lawsuits are weak?
Not necessarily. Reports indicate some jurors believed the device could have been made safer even though they could not reach a unanimous verdict on that specific claim, and the case involved a harder-to-prove infection injury; other bellwether trials focused on fracture and thrombosis injuries remain scheduled.
Is there a settlement?
No global settlement has been reached as of this update. The parties have been directed to participate in settlement talks later in 2026, but the unresolved design-defect issue from the first trial adds uncertainty to that process.
Who can potentially file a claim?
Generally patients who received a Bard PowerPort or similar implantable port catheter and experienced complications like infection, fracture, migration, or a blood clot. An attorney can evaluate your specific medical history and state filing deadline.